SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 19, 2003
-----------------
ASTHMA DISEASE MANAGEMENT, INC.
(Exact Name of registrant as specified in charter)
Delaware 033-01534-D 22-3253496
- -------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
1223 Berks Street, Suite 201, Philadelphia, PA 19125
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (215) 634-4101
----------------------------
(Former name or former address, if changed since last report.)
-------------------------------
Exhibit Index appears on page 4 hereof.
Item 4. Changes in Registrant's Certifying Accountant
On February 18, 2003, Ciro E. Adams, CPA ("Adams") resigned as the
independent auditor of Asthma Disease Management, Inc. (the "Company"). No
report provided by Adams during his engagement by the Company contained an
adverse opinion or a disclaimer of opinion, or was qualified or modified as to
uncertainty, audit scope, or accounting principles, other than Adams' audit
report dated September 7, 2001, of the balance sheet dated May 31, 2001, and the
related statements of operations, cash flows and changes in stockholders'
equity, which was modified as to the uncertainty of the Company to continue as a
going concern.
During the term of Adams' engagement by the Company, there were no
disagreements with Adams on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedures, which
disagreement, if not resolved to the satisfaction of Adams would have caused
Adams to make reference to the subject matter of the disagreement in connection
with Adams' report other than the following:
1. The failure of the Company to disclose the suspension of the operation
of its on-site clinical laboratory;
2. Restrictions regarding the scope of the audit; and
3. The failure of the Company to have its Form 10-QSB for the quarter ended
February 28, 2001 reviewed by an independent auditor, and its failure to
disclose such failure.
On August 30, 2001, the Board of Directors of the Company and Adams
discussed and resolved the disagreements referenced in numbers 1 through 3 above
as previously reported on Form 8-K filed with the Securities and Exchange
Commission on September 6, 2001.
Ciro E. Adams, CPA, advised the Company of its requirement to file timely
additional Forms 10-QSB and 10-KSB subsequent to his audit report dated
September 7, 2001.
Ciro E. Adams, CPA, reviewed the disclosure provided in this current report
on Form 8-K prior to its filing with Securities and Exchange Commission.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
By:_/s/ James F. O'Connor
----------------------------------------------
Name: James F. O'Connor
Title: Chairman of the Board of Directors
Date: February 26, 2003
3
EXHIBIT INDEX
Exhibit No.
16.1 Letter from Ciro E. Adams, CPA stating that it has reviewed the current
report on Form 8-K and has no objection to the statements made within such
report.
4